Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Liabilities from Discontinued Operations (2024 - 2025)

Valion Bio has reported Liabilities from Discontinued Operations over the past 2 years, most recently at 6000.0 for Q4 2025.

  • For Q4 2025, Liabilities from Discontinued Operations fell 60.0% year-over-year to 6000.0; the TTM value through Dec 2025 reached 6000.0, down 60.0%, while the annual FY2025 figure was 6000.0, 60.0% down from the prior year.
  • Liabilities from Discontinued Operations for Q4 2025 was 6000.0 at Valion Bio, down from 15000.0 in the prior quarter.
  • Over five years, Liabilities from Discontinued Operations peaked at 15000.0 in Q4 2024 and troughed at 6000.0 in Q4 2025.